Skip to content
Markets News
Stocks1 min read

Genmab Trial Reports 50% Lower Risk of Death in Interim Analysis

Makkler Newsroom
October 29, 2026 · Based on reporting by GlobeNewswire

The petosemtamab and pembrolizumab combination met both primary endpoints in a Phase 3 trial of PD-L1-positive head and neck cancer.

Key takeaways

  • The Phase 3 LiGeR-HN1 trial met its overall survival and objective response rate endpoints.
  • The combination reduced the risk of death by 50% versus pembrolizumab alone.
  • Genmab plans to engage global regulators and present full results at a future medical meeting.

Genmab said its petosemtamab and pembrolizumab combination reduced the risk of death by 50% versus pembrolizumab alone in a Phase 3 trial. The first interim analysis found the treatment met both primary endpoints in patients with PD-L1-positive recurrent or metastatic head and neck cancer.

The trial also found a statistically significant improvement in objective response rate, regardless of patients’ HPV status. Genmab said the combination’s safety profile was generally well tolerated, with no new safety signals identified.

As of Wednesday at 4 p.m. EDT, Genmab shares traded at $57.29, up 28.25% since the previous close. The company plans to engage global regulatory authorities and submit full trial results for presentation at a future medical meeting.

Topics

Comments (0)

Log in to join the discussion.Log in

No comments yet - be the first to weigh in.